Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD)

Overview

Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a serious extra-articular manifestation of RA, affecting up to 10% of RA patients clinically, though subclinical involvement may be present in up to 60% on HRCT. It typically presents in the 5th–6th decade, with a male predominance and is a leading cause of RA-related mortality. The most common histopathological subtype is usual interstitial pneumonia (UIP), which carries a worse prognosis than nonspecific interstitial pneumonia (NSIP). Risk factors include smoking, high RA disease activity, anti-CCP positivity, and MUC5B promoter variant. Complications include progressive pulmonary fibrosis and respiratory failure.

Definition

Interstitial Lung Disease (ILD): A group of disorders characterized by inflammation and fibrosis of the lung interstitium.
Usual Interstitial Pneumonia (UIP): A histologic pattern of ILD marked by patchy fibrosis and honeycombing, often seen in RA-ILD.
Anti-Cyclic Citrullinated Peptide (anti-CCP): Autoantibody highly specific for RA, associated with extra-articular manifestations.
High-Resolution Computed Tomography (HRCT): Imaging modality of choice for detecting ILD patterns.

Anatomy and Physiology

Respiratory System: The lungs are composed of airways (bronchi, bronchioles) and alveoli, which are tiny air sacs responsible for gas exchange. The interstitium is the space between the alveolar epithelial cells and the endothelial cells of the capillaries.
Gas Exchange: Oxygen diffuses from the alveoli into the capillaries, and carbon dioxide diffuses from the capillaries into the alveoli. The thinness of the alveolar-capillary membrane is crucial for efficient gas exchange.
Immune System in the Lung: The lung possesses its own immune cells (e.g., alveolar macrophages, lymphocytes) that provide defense against inhaled pathogens and irritants.
Fibroblasts: These are connective tissue cells that produce collagen and other fibers. In fibrotic lung diseases, fibroblasts become overactive and produce excessive amounts of extracellular matrix, leading to scarring.

Aetiology and Risk Factors

Aetiology

Autoimmune inflammation from RA targeting lung parenchyma
Genetic predisposition: MUC5B promoter variant
Environmental triggers: smoking, pollutants
Drug-induced (e.g., methotrexate, leflunomide — controversial)

Risk Factors

Male sex
Age >60
Smoking history
High RA disease activity (DAS28)
Anti-CCP and RF positivity
HLA-DRB1 shared epitope

Anti-CCP positivity is a stronger predictor of RA-ILD than RF alone.

Pathophysiology

RA triggers systemic immune activation → cytokine release (TNF-α, IL-6)
Lung epithelial injury → activation of alveolar macrophages and dendritic cells
Recruitment of T cells and B cells → autoantibody production
Fibroblast activation → extracellular matrix deposition
Progressive fibrosis → impaired gas exchange and restrictive lung physiology

Fibrosis in RA-ILD is not merely a consequence of inflammation but involves aberrant wound healing and epithelial–mesenchymal transition.

Clinical Manifestations

Dyspnea on exertion
Nonproductive cough
Bibasilar crackles on auscultation
Clubbing (less common than in IPF)
Hypoxia (especially during exertion)
Reduced exercise tolerance
Restrictive pattern on spirometry

Diagnosis

Diagnosis

RA diagnosis
HRCT evidence of ILD
Exclusion of other ILD causes

Investigations

HRCT: gold standard
- Identifies UIP (honeycombing, subpleural reticulation) vs NSIP (ground-glass opacities)
Pulmonary Function Tests: restrictive pattern, ↓ DLCO
Serology: RF, anti-CCP
BAL (bronchoalveolar lavage): lymphocytosis in NSIP
Lung biopsy: rarely needed, reserved for atypical cases

Differential Diagnoses

Condition	Differentiating Feature
IPF	Older age, absence of RA, rapid progression
Hypersensitivity pneumonitis	Exposure history, centrilobular nodules
Drug-induced ILD	Temporal relation to medication
Sarcoidosis	Noncaseating granulomas, hilar lymphadenopathy

Classification

Based on HRCT/histopathology:

Usual Interstitial Pneumonia (UIP) – most common
Nonspecific Interstitial Pneumonia (NSIP)
Organizing Pneumonia (OP)
Lymphoid Interstitial Pneumonia (LIP)

UIP subtype in RA-ILD mirrors IPF and carries worse prognosis.

UIP is common in RA-ILD, the other rheumatological conditions typically develop NSIP pattern.

Treatment

Immunomodulators:
- Methotrexate
- Mycophenolate mofetil
- Azathioprine
- Rituximab (especially in UIP)
Anti-fibrotics:
- Nintedanib (approved for progressive fibrosing ILD)
Corticosteroids: limited role, more effective in NSIP
Supportive:
- Oxygen therapy
- Pulmonary rehab
- Vaccinations (influenza, pneumococcus)

Nintedanib slows FVC decline in progressive RA-ILD.

Complications and Prognosis

Complications

Progressive pulmonary fibrosis
Respiratory failure
Pulmonary hypertension
Superimposed infections
Drug-induced lung injury

Prognosis

UIP subtype: median survival ~3–5 years
NSIP subtype: better prognosis
Poor prognostic factors:
- Older age
- Male sex
- UIP pattern
- Low DLCO
- High RA activity

Early detection and subtype identification are key to prognosis and treatment planning.

References

Kadura S, Raghu G. Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management. Eur Respir Rev. 2021;30(160):210011.
Dai Y, Wang W, Yu Y, Hu S. Rheumatoid arthritis–associated interstitial lung disease: an overview of epidemiology, pathogenesis and management. Clin Rheumatol. 2021;40:1211–1220.
Kim Y, Yang H-I, Kim K-S. Etiology and Pathogenesis of Rheumatoid Arthritis-Interstitial Lung Disease. Int J Mol Sci. 2023;24(19):14509.
Radiopaedia.org. Rheumatoid arthritis associated interstitial lung disease. Accessed 2025.
Sparks JA et al. Rheumatoid arthritis disease activity and risk of ILD. Springer. 2020.
European Respiratory Society. RA-ILD review. Eur Respir Rev. 2021.
Flaherty KR et al. Nintedanib in progressive fibrosing ILDs. N Engl J Med. 2019;381:1718–1727.
Kim EJ et al. Epithelial–mesenchymal transition in RA-ILD. J Immunol Res. 2022.